Get all the updates for this publication
Curcumin augments therapeutic efficacy of TRAIL-based immunotoxins in leukemia
Published in Springer Science and Business Media LLC
2020
Volume: 72
Issue: 4
Pages: 1032 - 1046
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) has been perceived as a promising anti-cancer agent because of its unique ability to kill cancer cells while sparing normal cells. However, translation of TRAIL to clinical studies was less successful as a large number of cancer cells acquire resistance to TRAIL-based monotherapies. An ideal strategy to overcome TRAIL resistance is to combine it with potential sensitizing agents.
Content may be subject to copyright.
About the journal
| Publisher | Data powered by TypesetSpringer Science and Business Media LLC |
|---|---|
| Open Access | No |
Authors (2)
Rama Shanker Verma- Trans-differentiation of human mesenchymal stem cells generates functional hepatospheres on poly(l-lactic acid)-co-poly(ε-caprolactone)/collagen nanofibrous scaffolds
- Breaking dogma for future therapy using stem cell - Where we have reached?
- Magnetic Nanoparticles Labeled Mesenchymal Stem Cells: A Pragmatic Solution toward Targeted Cancer Theranostics
- Application of microbial toxins for cancer therapy
R Madhumathi- Institutional ownership and earnings management in India
- An empirical evaluation of factors differentiating governance regulations across economies
- Do corporate diversification and earnings management practices affect capital structure?: An empirical analysis
- Inferring principles for sustainable development of business through analogies from ecological systems
